Evidence map›Paper›PMID 42776678›Full record

ArticleMethods and protocols2026

A Practical Workflow for Correcting Kit-Specific Effects in Whole-Exome Sequencing Data.

Laura Jarosz, Marcel Ochocki, Julia Merta, Lajos Pusztai, Michal Marczyk

Abstract read
In one paragraph

Article in Methods and protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Laura JaroszDepartment of Data Science and Engineering, Silesian University of Technology, 44-100 Gliwice, Poland.ORCID 0009-0004-5297-2407
Marcel OchockiDepartment of Data Science and Engineering, Silesian University of Technology, 44-100 Gliwice, Poland.
Julia MertaDepartment of Data Science and Engineering, Silesian University of Technology, 44-100 Gliwice, Poland.ORCID 0009-0005-8999-5036
Lajos PusztaiYale Cancer Center, New Haven, CT 06511, USA.ORCID 0000-0001-9632-6686
Michal MarczykDepartment of Data Science and Engineering, Silesian University of Technology, 44-100 Gliwice, Poland.ORCID 0000-0003-2508-5736

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
PHARMACOGENETICS OF PHASE II DRUG METABOLIZING ENZYMESU01GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2000 to 2009
$15.7M
National Science Centre 2023/50/E/NZ2/00583NCI NIH HHS N01 CA015083NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA116201NIGMS NIH HHS U01 GM061388NIGMS NIH HHS U19 GM061388
6 · The paper itself

Abstract

Large-scale, multi-center projects have become common in the era of rapid technological development, but protocol standardization remains challenging. In whole-exome sequencing (WES), various exome enrichment kits exhibit variable efficiency across genomic regions, leading to systematic, non-biological batch effects, much stronger than other technical factors. We propose a workflow to minimize the effect of WES capture inconsistencies in single-nucleotide variation (SNV) data. The pipeline consists of quality control, mapping to the genome, SNV calling, joint genotyping, and imputing genotypes using reference haplotypes. SNVs are then aggregated into gene-level features measuring the burden of deleterious variants. Finally, a gene-level imputation is performed using a customized algorithm. Namely, if the detection rate of a gene is low in samples enriched with a given capture kit but high in samples enriched with other kits, missing values in the former group are imputed, as such differences are unlikely to reflect true biology. As a benchmark, we conducted a study on over a thousand breast cancer cases across 11 cohorts, using eight exome capture kits. We demonstrated that the proposed pipeline leads to a considerable decrease in the batch effect signal, potentially increasing the likelihood of finding true biological signals.

Indexed as

batch effectexome capture kitgenetic variantsimputationwhole-exome sequencing

Identifiers

PMID42776678
PMCPMC13600025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.